key: cord-0798794-p16wximb authors: Han, Ying; Cao, Lu; Yuan, Kai; Shi, Jie; Yan, Wei; Lu, Lin title: Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse date: 2022-05-15 journal: Neurosci Bull DOI: 10.1007/s12264-022-00872-3 sha: 097a6e0c3edbc4b876ab04fef76940615d46b414 doc_id: 798794 cord_uid: p16wximb Fentanyl is a fully synthetic opioid with analgesic and anesthetic properties. It has become a primary driver of the deadliest opioid crisis in the United States and elsewhere, consequently imposing devastating social, economic, and health burdens worldwide. However, the neural mechanisms that underlie the behavioral effects of fentanyl and its analogs are largely unknown, and approaches to prevent fentanyl abuse and fentanyl-related overdose deaths are scarce. This review presents the abuse potential and unique pharmacology of fentanyl and elucidates its potential mechanisms of action, including neural circuit dysfunction and neuroinflammation. We discuss recent progress in the development of pharmacological interventions, anti-fentanyl vaccines, anti-fentanyl/heroin conjugate vaccines, and monoclonal antibodies to attenuate fentanyl-seeking and prevent fentanyl-induced respiratory depression. However, translational studies and clinical trials are still lacking. Considering the present opioid crisis, the development of effective pharmacological and immunological strategies to prevent fentanyl abuse and overdose are urgently needed. Fentanyl was initially designed and synthesized as a valuable therapeutic for anesthesia and severe pain management. It exerts analgesic and rewarding effects by binding to and activating l-opioid receptors (MORs). Fentanyl has unique pharmacological properties, including a rapid onset of action, high potency at activating MORassociated signaling in vivo (100-fold more potent than morphine), high lipophilicity, and the induction of muscle rigidity. Fentanyl abuse and overdose are becoming increasingly more common [1, 2] . Moreover, fentanyl is commonly mixed with cocaine, methamphetamine, heroin, and other illicit drugs among addicts. Over 40% of opioiddependent people who inject drugs report lifetime purposeful fentanyl use, which is independently correlated with younger age, recent daily injection, and moderate/severe depression [3] . In the United States, urine drug test data has shown that positivity rates for non-prescribed fentanyl increased 1850% (from 0.9% in 2013 to 17.6% in 2018) among cocaine-positive samples and increased 798% (from 0.9% in 2013 to 7.9% in 2018) among methamphetaminepositive samples [4] . Positivity rates of co-occurring methamphetamine, cocaine, and heroin have also increased since 2013 among fentanyl-positive urine drug test results [5] . Fentanyl abuse is rarely found in China, and its manufacture, consumption, and storage are strictly controlled [6] [7] [8] [9] . All fentanyl-related substances have been included in the supplementary list of controlled narcotic drugs and psychotropic substances with non-medical use in China since May 1, 2019 [10] (http://www.mps.gov.cn/ n2254314/n2254487/c6473090/content.html). Before and during the COVID-19 pandemic, the misuse and abuse of fentanyl appear to have persistently increased in the United States and elsewhere [11] . Overdose deaths and infections among people who use drugs, including fentanyl, increased during the COVID-19 crisis [12] [13] [14] . A study in Ontario, Canada, showed that fentanyl use increased by 108% among patients who were treated with opioid receptor agonists [15] . These patients have a high risk of COVID-19 infection, and their treatment can be problematic under conditions of quarantine and isolation and considering the scarcity of healthcare resources during the pandemic [16] . Prescription fentanyl demand has increased in critically ill COVID-19 patients who require mechanical ventilation, resulting in a shortage of intravenous fentanyl. The combined use of intravenous and transdermal fentanyl may be an option [17, 18] . However, intravenous fentanyl administration can disrupt brainstem respiratory systems, trigger respiratory depression, and impair the microcirculatory compensatory response to hemorrhage in the brainstem and lungs. Therefore, COVID-19 patients who use fentanyl should be closely monitored to avoid the exacerbation of clinical outcomes [19] [20] [21] . The present review introduces the receptor pharmacology and behavioral effects of fentanyl and elucidates the potential neural mechanisms that underlie fentanyl abuse from different perspectives, including neural circuit dysfunction and neuroinflammation. We also discuss the progress in the development of pharmacological interventions and active immunopharmacotherapies to attenuate fentanyl abuse and its side-effects. Despite its widespread use for chronic pain and severe cancer pain in the clinical setting, fentanyl and its analogs have been shown to produce hyperlocomotion and strong rewarding and reinforcing effects and have abuse potential. Fentanyl induces a strong rewarding and reinforcing effects, which is the main contributor to its abuse and overdose deaths [22, 23] . Similar to morphine, fentanyl and its analogs, including isobutyrylfentanyl, crotonylfentanyl, para-fluorobutyrylfentanyl, b-methylfentanyl, paramethoxyfentanyl, fentanyl carbamate, and 3-furanylfentanyl, have MOR agonist-like hyperlocomotor effects in mice [24] [25] [26] . Self-administration models are commonly used to evaluate the reinforcing effects of drugs. Both male and female rats exhibit stable fentanyl self-administration, drugprimed reinstatement, and yohimbine (stress)-and cueinduced reinstatement [27] . When rats self-administer fentanyl with short access (ShA; 1 h are trained to duration daily) or long access (LgA; 6 h duration daily), both ShA and LgA rats exhibit an increase in craving during fentanyl-, yohimbine-, and cue-induced reinstatement [27] , indicating strong fentanyl abuse potential. Monroe and Radke established an aversion-resistant fentanyl self-administration model in mice, and found that when quinine is added to the fentanyl solution, mice still robustly respond and consume the solution in both a home-cage two-bottle choice task and operant response task [28] . In addition, a fentanyl vapor selfadministration model has been successfully established in mice. This model recapitulates key features of opioid addiction, including the escalation of fentanyl intake, somatic signs of withdrawal, punishment-resistant fentanyl intake, and relapse [29] . A study that combined fentanyl vapor self-administration and a behavioral economics approach found more inelastic demand for fentanyl and an increase in maximal response output in LgA (12 h) rats compared with ShA (1 h) rats [30] . These studies indicate that fentanyl is a powerful addictive drug with high abuse potential, which partially explain the sharp rise in fentanyl abuse in recent years. Although chronic high-dose fentanyl administration reduces anxiety-like behavior, lowers sensitivity to painful stimuli, and decreases sensitivity to cocaine, fentanyl withdrawal increases anxiety-like behavior [31] . Spontaneous and naloxone-precipitated withdrawal from 2 weeks of intermittent fentanyl exposure also causes weight loss and increases signs of distress in both mice and rats [32] . States of opioid dependence and withdrawal can profoundly influence fentanyl reinforcement and the efficacy of therapeutic medications. The reinforcing effects of fentanyl increase in morphine-withdrawn rats, reflected by a rightward shift of the fentanyl dose-response curve with an increase in maximal effectiveness, whereas the reinforcing effects of fentanyl decrease in opioid-dependent rats [33] . However, no antinociceptive cross-tolerance occurs with repeated microinjections of morphine and fentanyl into the ventrolateral periaqueductal gray, which may be attributable to the different signaling mechanisms that mediate morphine-and fentanyl-induced antinociception [34, 35] . The behavioral effects of fentanyl administration are influenced by sex, animal strain, and genetic and environmental factors. Fentanyl potently induces an acute locomotor response and behavioral sensitization in female rats but more potently induces contextual reward in a conditioned place preference paradigm in male rats [36] . Under a fixed-ratio 5 schedule of reinforcement and multiday progressive-ratio schedule in a behavioral economics analysis, female rats exhibit greater reinforcing efficacy of fentanyl than male rats. In a fentanyl versus. food choice procedure, male rats are more sensitive to fentanyl than females [37] . Remifentanil self-administration-induced neuroadaptations have been shown to differ between males and females, indicating that sex-specific interventions that target opioid-induced adaptations should be developed [38] . Species differences have been found in the expression of fentanyl withdrawal-associated pain. Spontaneous and ongoing pain is preferentially expressed in rats, whereas withdrawal-associated thermal hyperalgesia is found only in mice [32] . Genetic and environmental factors influence the risk of opioid use disorder. Hnrnph1 mutant mice exhibit lower behavioral sensitivity to fentanyl, suggesting that the expression of this gene may be a biomarker that reflects addictive properties [39] . Fentanyl is known to be a strong MOR agonist, similar to other opioids, such as morphine. The structural assessment of agonist efficacy at MORs has revealed different patterns between fentanyl and morphine [40, 41] . Principal component analysis and computational functional analysis have identified differences in ligand binding, intracellular signaling events, and receptor conformational changes between fentanyl and morphine, which may contribute to the greater efficacy of fentanyl over morphine [40] [41] [42] . Chevalier et al. exploited the X-ray structure of the MOR in complex with fentanyl and elucidated detailed fentanyl-MOR interaction profiles, thus providing a structural basis for the binding affinity, ligand recognition, and abuse potential of fentanyl and its analogs [43] . Using molecular dynamics techniques to identify binding events of the MOR with fentanyl and its analogs carfentanil and lofentanil, a previous study found that fentanyl induces the unique rotameric conformation of M153, which is required for inducing b-arrestin coupling [44] . These studies provide structural and molecular insights into the detailed mechanisms by which fentanyl binds to MORs, which is helpful for the further optimization of fentanylbased analgesics with fewer side-effects and improved safety and efficacy. Fentanyl and its analogs can have serious side-effects, such as increases in brain and kidney levels of malondialdehyde, neuroadaptive changes in the brain, and acceleration of the onset of acute postoperative pain [45, 46] . After exposure to fentanyl and its analogs in rats, the metabolite norfentanyl has been detected at high concentrations in urine and remains detectable for 3 days [47] . Fentanyl and its analogs have weak binding affinity for jopioid receptors, d-opioid receptors, and the r1 receptor, which could contribute to the pharmacological actions and side-effects of these drugs [22, 48] . Fentanyl also interacts with non-opioid recombinant human neurotransmitter receptors and transporters, such as the a1A and a1B adrenoceptor subtypes and the dopamine D 1 and D 4 receptor subtypes [49] . Human ether-a-go-go-related gene channels have been associated with fentanyl-induced sudden death, and this is exacerbated by hypoxia, hypokalemia, or alkalosis [50, 51] . The complex receptor pharmacology of fentanyl contributes to the different clinical manifestations of fentanyl use, including respiratory and cardiothoracic side-effects and overdose deaths. Recent studies have reported that fentanyl inhibites the viability and invasion of non-small-cell lung cancer cells by reversing the expression of microRNA-331-3p and histone deacetylase 5 [52] . Fentanyl has been shown to have anti-leukemia activity via suppression of the STAT5 and Ras pathways [53] . Fentanyl inhibits the progression, invasion, and migration of gastric cancer cells by suppressing activity of the phosphoinositide 3-kinase (PI3K)/ protein kinase B (Akt)/matrix metalloprotoneinase-9 signaling pathway [54] . Fentanyl also stimulates tumor angiogenesis and promotes the migration of some but not all tested human lung cancer cells; this may be related to the activation of multiple pro-angiogenic signaling pathways, including vascular endothelial growth factor receptor 2/focal adhesion kinase/PI3K/Akt and small guanosine triphosphatases [55] . This study indicates that fentanyl use in cancer patients may have potential adverse effects and should be administered with caution. The b-arrestin 2 pathway plays an important role in recovery from opioid overdose [56] , and ketamine may help attenuate some of the adverse physiological consequences of fentanyl use [21] . Li et al. found that ketamine combined with fentanyl and dexmedetomidine induces safer and more efficient anesthesia than ketamine alone [57] . These studies provide insights into the molecular basis and signaling pathways that mediate the multiple pharmacological effects of fentanyl and its analogs. Perinatal fentanyl exposure in newborn male and female mice leads to signs of spontaneous somatic withdrawalrelated behavior, an increase in anxiety-like behavior, and impaired sensory function that lasts at least to adolescence [58, 59] . Moreover, this exposure impaires synaptic transmission in the somatosensory cortex (SC) and anterior cingulate cortex (ACC), reduces ketamine-evoked cortical oscillations, and reduces the morphology of basal dendrites of pyramidal neurons in the SC [59] . Fentanyl binds to MORs in molecular-layer interneurons to reduce caminobutyric acid (GABA)ergic neurotransmission to Purkinje cells, thus inhibiting sensory information processing [60] . In addition, fentanyl and morphine exposure during therapeutic hypothermia does not impair neurodevelopment and does not significantly affect cognition, language, or motor function in infants, but the long-term effects need further investigation [61] . Here, we describe the potential neural mechanisms that are involved in the pathophysiology of fentanyl abuse and fentanyl-related side-effects ( Fig. 1 ). Drug addiction is viewed as a disorder of dopamine neurotransmission and the reward system in the brain, especially dopamine-releasing neurons in the ventral tegmental area (VTA) and its extensive projections [62, 63] . Previous studies have shown that fentanyl vapor self-administration causes long-lasting neuroadaptations of GABA B receptor-mediated currents in VTA dopamine neurons [29] . Both subcutaneous and intravenous fentanyl administration significantly increase dopamine release in the nucleus accumbens (NAc) and have reinforcing effects [64] . RNA sequencing has revealed that repeated fentanyl withdrawal elicits distinct transcriptional activity in the VTA and NAc in male and female rats [65] . In addition, fentanyl exhibits an affinity for, and effects on, recombinant human neurotransmitter transporters, including dopamine receptor subtypes [49] . These studies indicate that the dopamine system mediates the rewarding and reinforcing effects of fentanyl abuse. The orexin system is involved in the pathophysiology of opioid addiction, and orexin receptor antagonism attenuates drug-seeking behavior and relapse [66, 67] . Intermittent fentanyl self-administration induces a multifaceted addiction-like state and increases the number of orexin neurons in both the dorsomedial/perifornical hypothalamus and lateral hypothalamus [68] . The orexin receptor 1 antagonist SB-334867 decreases fentanyl intake, decreases motivation for fentanyl, and attenuates the cue-induced reinstatement of fentanyl-seeking [68, 69] . Intravenous fentanyl also decreases glutamate release and increases GABA release in the anterior hypothalamus, measured by the push-pull superfusion technique, and this is reversed by intrahypothalamic administration of the opioid receptor antagonist naloxone [70] . In addition, corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis (BNST) is a critical driver of stress-induced relapse to drug-seeking. Intra-BNST microinjections of the CRF 1 receptor antagonist R121919 decreases cue-induced fentanyl-seeking and fentanyl-associated conditioned reinforcement in rats [71] . The SC and dorsal raphe nucleus (DRN) are critical regions involved in nociception and may also play a critical role in the process of fentanyl misuse. Fentanyl administration alteres the firing activity of neurons and serotonin (5-hydroxytryptamine, 5-HT) efflux in the DRN, which may involve both opioid and 5-HT 1A receptors [72, 73] . Autoradiographic mapping has shown that sufentanil tolerance is associated with the large-scale downregulation of MOR binding sites in various brain regions, including the DRN and SC [74] . Fentanyl decreases synaptic excitation and inhibits nociceptive stimulus-induced cortical activity in both the ACC and SC [59, 75] . Synchronization between the right SC and right hippocampus is Fig. 1 Schematic of potential neural mechanisms of fentanyl abuse. Specific types of neurons and neural circuits that are involved in fentanyl taking and seeking are shown in a sagittal cross-section of the brain. SC, somatosensory cortex; ACC, anterior cingulate cortex; VTA, ventral tegmental area; NAc, nucleus accumbens; Hypo, hypothalamus; BNST, bed nucleus of the stria terminalis; PrL, prelimbic cortex; OFC, orbitofrontal cortex; Pir, piriform cortex; DRN, dorsal raphe nucleus. also impaired postoperatively after anesthesia with fentanyl and droperidol [76] . Chronic drug use is often accompanied by the loss of cognitive control, which is closely linked to the dysfunction of frontal cortex regions. Remifentanil self-administration causes a long-lasting hypoactive basal state of pyramidal neurons in the prelimbic cortex (PrL) in females, and this is driven by a reduction of a-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid receptor-mediated excitatory synaptic transmission [38] . In addition, remifentanil self-administration has bidirectional effects on PrL layer 5/6 pyramidal neuron GABA B -G protein-coupled inwardly rectifying K ? channel signaling in males [38] . Moreover, the chemogenetic activation of PrL pyramidal neurons reverses the deficits in cognitive flexibility, the basal hypoactive state, and remifentanil-induced plasticity [38] . Reiner et al. developed a rat model of relapse to drugseeking after food choice-induced voluntary abstinence and found that relapse to fentanyl-seeking is associated with an increase in activation in the orbitofrontal cortex (OFC) and its projection from the piriform cortex (Pir) but not in projections from the basolateral amygdala or thalamus. Using pharmacological inactivation and the anatomical disconnection of projections between the Pir and OFC, previous studies found that Pir-OFC projections play a critical role in relapse to fentanyl-seeking after voluntary abstinence [77, 78] . Future studies that use neural circuitdefined imaging and manipulation techniques may shed further light on the neurobiology of fentanyl relapse. Opioid misuse, tolerance, and withdrawal have been reported to induce innate and adaptive neuroimmune dysfunction, affect neuronal function, and modulate the activation and phenotyping of microglial cells, thus producing proinflammatory effects in the brain [79] . Fentanyl self-administration profoundly alters innate immune proteins in the NAc and hippocampus. Fentanyl administration increases the expression of cytokines (e.g., tumor necrosis factor a [TNFa], interleukin-1b [IL-1b], and IL5), chemokines (e.g., C-C motif chemokine 20), and interferon (IFN) proteins (e.g., IFNb and IFNc) in the NAc, decreases several interleukins (e.g., IL-4 and IL-7), chemokines (e.g., granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein 1, and chemokine ligand 5), and interferons (e.g., IFNb and IFNc), and stimulates IFN gene protein expression in the hippocampus, which may initiate fentanyl misuse and perhaps the development of opioid use disorder [80, 81] . Fentanyl administration increases mechanical and thermal hyperalgesia, increases the expression of proinflammatory cytokines (e.g., IL-1b, IL-6, and TNF-a) in the spinal cord and dorsal root ganglia, and activates microglia in the spinal cord in rats [82] . Repeated fentanyl administration activates the NLRP3 inflammasome in astrocytes and serotonergic neurons and promotes NLRP3-dependent pyroptosis in the DRN. Furthermore, the antiinflammatory agent minocycline and the NLRP3 inhibitor MCC950 prevent fentanyl-induced antinociception and hyperalgesia [83] . Fentanyl has also been shown to reverse the lipopolysaccharide-induced release of TNF-a, IL-1b, and IL-10 by inhibiting Toll-like receptor-4 (TLR4) expression and glycogen synthase kinase-3b activation [84] . These studies indicate that neuroinflammation plays an important role in opioid-induced analgesia and fentanyl-induced hyperalgesia. Gut microbiota and gut-brain communication also play a critical role in opioid use and opioid tolerance [85, 86] . Chronic opioid use alters fecal microbial diversity and composition and induces gut microbial dysbiosis in both rodents and humans, accompanied by increases in peripheral and central inflammation [87] [88] [89] . Moreover, microbial metabolites, such as short-chain fatty acids, are reduced, and intestinal and blood-brain barrier integrity is disrupted after opioid use, which could modulate the development, maturation, and function of microglia and exacerbate the neuroimmune responses [87, 89, 90] . Neuroinflammation that is induced by alterations of the microbiota can ultimately contribute to behaviors that are associated with opioid dependence [91, 92] . However, the effects of fentanyl use on the gut microbiota remain unknown. Future studies are needed to investigate the influence of alterations of the microbiota on brain immunity and function. Pharmacotherapies that target brain opioid receptors, including agonists (e.g., methadone and buprenorphine) and antagonists (e.g., naltrexone and naloxone), have been approved by the Food and Drug Administration (FDA) for the treatment of opioid use disorder. A meta-analysis has shown that these treatments can reduce mortality among opioid users [93] . A long-acting injection of extendedrelease buprenorphine has been shown to be feasible for users of heroin-containing fentanyl in an open-label trial [94] . However, these pharmacotherapies are limited by high relapse rates, a high risk of precipitating withdrawal in individuals who are exposed to fentanyl, and weak efficacy in preventing fentanyl overdose [95] . Thus, new approaches and novel medications are still needed for the treatment of opioid use disorder. Here, we summarize the currently available pharmacological interventions to attenuate fentanyl taking and seeking in rodents and nonhuman primates (Table 1) . These interventions mainly target opioid receptors and neurotransmitter and neuropeptide systems. Intravenous and subcutaneous administration of the long-lasting MOR antagonist methocinnamox reverses and prevents fentanyl-induced antinociception and respiratory depression in rats [96] . Methocinnamox attenuats heroin self-administration in rhesus monkeys, which continues to display efficacy even at very low plasma levels [97] . Contingent administration of the j-opioid receptor agonists U50488 and nalfurafine decrease fentanyl choice, which is blocked by the selective j-opioid receptor antagonist norbinaltorphimine [98] . Levo-tetrahydropalmatine is an antagonist of dopamine receptors that suppresses the rewarding effects of fentanyl in the conditioned place preference paradigm by inhibiting the phosphorylation of extracellular signal-regulated kinase (ERK) and cyclic adenosine monophosphate response element binding protein (CREB) in the hippocampus, NAc, and prefrontal cortex in mice [99] . The acute stimulation of 5-HT 2A receptors with the psychedelic 2,5-dimethoxy-4-iodoamphetamine decreases the economic demand for fentanyl and food after intermittent and continuous-access self-administration [100] . In a rat model of relapse, the glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4 reduces fentanyl self-administration in rats but causes malaise-like behavior. A novel dual agonist of GLP-1Rs and neuropeptide Y 2 receptors, GEP44, reduces fentanyl self-administration with fewer adverse effects compared with exendin-4 [101, 102] . The growth hormone secretagogue receptor antagonist JMV2959 reduces fentanyl-induced conditioned place preference and fentanyl self-administration [64] . The glucocorticoid receptor antagonist PT150 reduces footshock-induced fentanyl-seeking [103] . Intra-BNST injections of the CRF 1 receptor antagonist R121919 deceases cue-induced responding to fentanyl in both opioid-dependent and nondependent rats [71] . Compared with ShA and LgA to fentanyl, intermittent access increases the motivation for fentanyl and total intake, which is reversed by the orexin receptor-1 antagonist SB334867 [68] . Fentanyl overdose fatalities and the opioid crisis are mainly attributable to drug-induced respiratory depression. Fentanyl overdose induces hippocampal ischemia, accompanied by delayed leukoencephalopathy [104] . Fentanyl but not morphine alters mitochondrial morphology, depending on the dosage and cell type, and this may be associated with neuronal apoptosis [105, 106] . Fentanyl-induced respiratory depression is associated with electrocortical changes, underscoring the importance of considering the activity of cortical and subcortical areas when evaluating fentanyl-induced respiratory depression [107] . Fentanyl and its analogs can rapidly produce airway closure and rigidity in the upper airway and diaphragm chest wall, which may involve a-adrenergic and cholinergic receptormediated mechanical failure of the respiratory and cardiovascular systems [49, 108] . We summarize currently available pharmacological interventions to prevent fentanyl-induced respiratory depression in Table 2 . D-amphetamine hastens the recovery of arterial pH and partial pressure of CO 2 , O 2 , and sO 2 in rats, promotes the alleviation of respiratory depression, and escalates the return of consciousness following high-dose fentanyl [109] . The G protein-biased cannabinoid CB 2 receptor agonist LY2828360 decreases fentanyl-induced respiratory depression in wildtype mice but not in G proteinbiased CB 2 receptor knockout mice [110] . The acyclic cucurbit[n]uril molecular container calabadion 1 reverses fentanyl-induced respiratory depression in rats [111] . The selective a4b2 nicotinic receptor agonist A85380 confers robust and rapid reversal of fentanyl-induced respiratory depression, without any obvious side effects. A85380 also significantly decreases respiratory depression and apnea when co-administered with fentanyl and remifentanil [112] . Brackley et al. found that the peptide oxytocin receptor agonist oxytocin acetate and the non-peptide oxytocin receptor agonist WAY-267464 without vasopressin-1A receptor cross-activation rescues fentanyl-induced respiratory depression [113] . The clinically approved superoxide dismutase mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (Tempol) has also been reported to attenuate the cardiorespiratory depressant effects of fentanyl without affecting its analgesic effects [114] . Altogether, mounting preclinical data provide proof-ofconcept of the efficacy of potential pharmacological interventions to attenuate fentanyl-seeking and prevent fentanyl-induced respiratory depression, demonstrating their potential for the treatment of fentanyl abuse and overdose. However, translational studies and clinical trials still need to be conducted. The management and prevention of fentanyl-related overdoses are notable challenges. Anti-opioid vaccines may be a promising therapeutic approach to prevent opioid overdose and reduce opioid-induced behavior, including drug self-administration in mice, rats, and nonhuman primates [14, 115] . Vaccines produce fentanyl-specific antibodies and sequester large amounts of these drugs in blood, thus reducing biodistribution in the brain and preventing binding to targeted receptors in the brain [116, 117] . Compared with FDA-approved small-molecule pharmacotherapies (e.g., methadone, buprenorphine, and naltrexone), fentanyl vaccines offer several potential clinical benefits, including prolonged protection because of the relatively long serum half-life, fewer side-effects by directly binding and sequestering drugs in the periphery, high selectivity, and no abuse liability. Vaccines that target opioids (e.g., heroin, morphine, oxycodone, and hydrocodone) and psychostimulants (e.g., cocaine and methamphetamine) have shown promising results in animal models and are currently in various stages of preclinical development [118] [119] [120] [121] . Anti-fentanyl vaccines are still in the early stages of development. Currently, several fentanyl and fentanyl/heroin vaccines have been developed with different designs (Fig. 2) , including the optimization of fentanyl-based haptens and linker chemistry, the choice of carrier proteins and adjuvants, delivery strategies, and the development of novel carriers and delivery platforms (Table 3) . Considering the devastating opioid crisis worldwide, different carrier proteins, adjuvants, delivery strategies, and fentanyl-based haptens are being developed to improve fentanyl vaccine efficacy, shelf life, and safety. A vaccine that consists of a fentanyl-based hapten that is conjugated to the keyhole limpet hemocyanin (KLH) carrier protein or GMP-grade subunit KLH reduces fentanyl distribution in the brain and reduces fentanyl-induced antinociception and respiratory depression in mice and rats [122] . Fentanyltetanus toxoid (TT) conjugate vaccines elicit high antifentanyl antibody titers and ablate lethal doses of fentanyl and its analogs, including 3-methylfentanyl and amethylfentanyl [123] . A fentanyl-TT conjugate vaccine has also beenreported to decrease fentanyl reinforcement, increase food reinforcement in a fentanyl versus. food choice procedure, and prevent the expression of opioid withdrawal-associated increases in fentanyl choice in male and female rats [124, 125] . Carfentanil is *100-fold more potent than fentanyl and can be lethal at extremely low doses. Pretreatment with the opioid receptor antagonist naltrexone decreases the seeking of fentanyl and heroin but not carfentanil [126] . Recently, two synthetic vaccines, Carfen-ester-TT and Carfen-p-phenyl-TT, have been shown to reduce carfentanil biodistribution in the brain and blunt carfentanil-induced antinociception and respiratory depression [127] . A recent study found that a fentanyl vaccine that is adjuvanted with a heat-labile toxin of E. coli, including dmLT and LTA1, elicits higher levels of anti-fentanyl antibodies than the traditional adjuvant alum. Vaccination with sublingual dmLT or intranasal LTA1 confers the robust blockade of fentanyl-induced analgesia and strong central nervous system penetration of anti-fentanyl antibodies [128] . This study also found that dmLT and LTA1 adjuvants and mucosal delivery enhance the immunogenicity and efficacy of fentanyl conjugate vaccines. A novel fentanyl vaccine, composed of a novel fentanyl hapten (para-AmFenHap), a safe and immunogenic carrier protein TT, and a potent liposomal adjuvant (ALF43A) that contains monophosphoryl lipid A, has also been synthesized and shown to prevent the side-effects of fentanyl [129] . The stimulation of TLR5 may also be an option to improve antibody production and enhance innate and adaptive immunity during active vaccination against Fig. 2 Design and production of fentanyl and fentanyl/heroin conjugate vaccines. Using synthetic chemistry, a specific linker is added to the fentanyl or fentanyl/heroin without affecting biological functionality to create a hapten. Linkage of the fentanyl or fentanyl/ heroin hapten to the carrier protein occurs through bioconjugate chemistry, and subsequent adjuvating of the immunologic stimulant generates complete vaccines. These vaccines have been tested in mice, rats, and nonhuman primates, where they have been shown to enhance innate and adaptive immunity, produce fentanyl-specific antibodies, sequester opioid drugs in the periphery, and prevent them from entering the brain, thus attenuating the reinforcing effects of fentanyl or fentanyl-contaminated heroin. IV, intravenous; IM, intramuscular; SC, subcutaneous; IP, intraperitoneal. fentanyl and its analogs [130] . Robinson et al. developed prophylactic vaccination and therapeutic vaccination that consists of novel fentanyl-based haptens that are conjugated to carrier proteins. Prophylactic vaccination reduces fentanyl-and sufentanil-induced respiratory depression, antinociception, and bradycardia in mice and rats, and therapeutic vaccination reduces fentanyl self-administration in rats [131] . Wang et al. developed a new fentanyl conjugate vaccine that is conjugated to the Gala1-3Gal epitope, which is based on preformed antibody-assisted antigen presentation, and this vaccine reduces fentanylassociated side-effects [132] . In non-opioid-dependent rats and rhesus monkeys, fentanyl vaccine administration blunts fentanyl reinforcement and increases food reinforcement for a prolonged period [124, 133] . A fentanyl-CRM 197 conjugate vaccine produces anti-fentanyl antibodies and attenuates fentanyl versus. food choice in male and female rhesus monkeys [133] . A fentanyl-TT conjugate vaccine increases plasma fentanyl levels *6fold and shifts fentanyl potency at least 10-fold in both schedule-controlled responding and thermal nociception assays in male rhesus monkeys [134] . Monoclonal antibodies (mAbs), especially 6A4, have been generated in hybridomas derived from mice vaccinated with a fentanyl conjugate vaccine. These mAbs have been reported to sequester large amounts of these drugs in blood, reverse fentanyl/carfentanilinduced antinociception, and prevent fentanyl-induced lethality, which could be a promising approach to treat opioid overdose and opioid use disorder [135] . a-Fentanyl mAbs have been generated from mice immunized with a fentanyl-sKLH conjugate vaccine. Pretreatment with these mAbs reduces fentanyl-induced antinociception, respiratory depression, and bradycardia in mice and rats [136] . These studies indicate that mAbs against fentanyl and its analogs have potential applications for the treatment of opioid use disorder and the prevention of overdose and toxicity. Overdose deaths caused by opioids have increased substantially in recent years, attributable to the adulteration of these drugs with fentanyl. Many immunopharmacotherapeutic studies have focused on developing new vaccines that can effectively target dual haptens to produce antibodies that are able to sequester fentanyl and contaminated opioids in the periphery. Blake et al. developed a heroin/fentanyl combination vaccine that consists of inulin-based formulations (Advax) that contain a CpG oligodeoxynucleotide and act as effective adjuvants when combined with a heroin conjugate. This vaccine produces high-opioid-affinity serum antibodies and reduces antinociception in both mice and cynomolgus monkeys [137] . By implementing an optimized dual hapten, a vaccine has been developed to produce antibodies that are able to bind fentanyl-contaminated heroin in the periphery, thus effectively blocking their analgesic effects [138] . A dual fentanyl/heroin vaccine generates high-affinity anti-fentanyl and anti-heroin antibodies and decreases the antinociceptive potency of a fentanyl/heroin mixture but does not attenuate combined fentanyl/heroin self-administration [139] . By combining TT-6-AmHap (a heroin monovalent vaccine) and TT-para-AmFenHap (a fentanyl monovalent vaccine) to formulate a bivalent vaccine that is adjuvanted with liposomes that contain monophosphoryl lipid A adsorbed on aluminum hydroxide, a study found that this bivalent conjugate vaccine induces dual immunogenic responses that ablate the effects of both heroin and fentanyl in mice [140] . A chemically contiguous heroin-fentanyl vaccine that uses a hapten with one epitope that has domains for both fentanyl and heroin has also been developed. This vaccine confers protection against heroin and fentanyl in an antinociception analysis [141] . Admixture vaccination strategies have also been applied to target two different drug species and combat fentanyl-adulterated heroin [142, 143] . These new fentanyl/ heroin vaccines appear promising but need further testing for possible translation to clinical use. In conclusion, fentanyl and its analogs have complex receptor pharmacology and produce multifaceted behavioral effects and clinical characteristics, including analgesia, anesthesia, sedation, and respiratory and cardiothoracic side-effects. Fentanyl transdermal microneedles have a rapid onset of antinociceptive action, providing an effective mode of opioid delivery for immediate pain relief with limited side-effects [144] . Microneedles that are loaded with low doses of fentanyl may reduce the risk of overdose fatalities. Developing novel technologies to reduce the clinical dose of fentanyl may be useful for mitigating the opioid crisis. Mechanistically, the behavioral effects of fentanyl likely result from a combination of its chemistry, receptor pharmacology, receptor signaling, rapid distribution to the central nervous system, neural circuit dysfunction, and neuroinflammation. However, the detailed neurobiological mechanisms that contribute to fentanyl abuse and overdose remain largely unknown. Novel effective pharmacological and psychosocial treatments and vaccines are urgently needed. Drug self-administration procedures and investigations of the choice between opioids and non-drug reinforcers are recommended to evaluate the effectiveness of candidate interventions in preclinical studies. States of opioid dependence and withdrawal should also be considered because such states can profoundly influence the results. The currently available small-molecule pharmacotherapies that mainly target MORs have limited efficacy to combat fentanyl abuse and overdose. Further elucidation of the molecular and structural bases of biased signaling and interactions between fentanyl and MORs is promising for optimizing fentanyl-based analgesics with fewer side-effects, a better safety profile, and higher efficacy. Future studies are needed to improve the effectiveness of opioid medications, such as G-protein biased MOR agonists, and develop novel non-opioid medications that target other systems, such as neurotransmitter and neuropeptide systems. Traditional Chinese medicine, including herbal therapy and acupuncture, has few side-effects and could also be considered for the treatment of fentanyl addition [145] [146] [147] . Anti-fentanyl vaccines produce antibodies that sequester opioid drugs in the periphery and prevent them from entering the brain and activating reward circuits. They have high selectivity and long-lasting efficacy and do not interfere with endogenous opioids, thus providing safe and cost-effective interventions for the management of fentanyl abuse and overdose. However, although several fentanyl and fentanyl/heroin vaccines have been shown to be effective in rodents and nonhuman primates, these vaccines are still in preclinical stages and need to be translated to the clinical treatment of opioid use disorder and fentanyl overdose. To facilitate preclinical-to-clinical translation and increase the success of drug discovery, it is critical to develop clinically viable formulations and optimize rational vaccine designs to maximize efficacy, understand the immunological mechanisms that underlie drug-motivated behavior and vaccine-evoked immune responses, and identify biomarkers that are predictive of individual variability and support patient stratification. The epidemic of fentanyl misuse and overdoses: Challenges and strategies Fentanyl analogues potency: What should be known Purposeful fentanyl use and associated factors among opioid-dependent people who inject drugs Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine Evaluation of trends of near-real-time urine drug test results for methamphetamine, cocaine, heroin, and fentanyl Recent trends in drug abuse in China Drug abuse in China: Past, present and future The new pattern of drug abuse in China The abuse of anesthetic propofol: Associated with cognitive impairment Control of fentanyl-related substances in China The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis Converging public health crises: Substance use during the coronavirus disease 2019 pandemic Changes in characteristics of drug overdose death trends during the COVID-19 pandemic The hidden epidemic of opioid overdoses during the coronavirus disease 2019 pandemic Evidence of increased fentanyl use during the COVID-19 pandemic among opioid agonist treatment patients in Ontario. Canada Editorial: Challenges to opioid use disorders during COVID-19 A novel clinical consideration to conserve parenteral fentanyl during the COVID-19 pandemic Clinical outcomes of concomitant use of enteral and intravenous sedatives and analgesics in mechanically ventilated patients with COVID-19 COVID-19 pandemic and fentanyl use disorder in African Americans Disruption of the rhythmic activity of the medullary inspiratory neurons and phrenic nerve by fentanyl and reversal with nalbuphine Fentanyl impairs but ketamine preserves the microcirculatory response to hemorrhage Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors Opioid-like antinociceptive and locomotor effects of emerging fentanyl-related substances Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated Escalation and reinstatement of fentanyl self-administration in male and female rats Aversion-resistant fentanyl self-administration in mice Fentanyl vapor self-administration model in mice to study opioid addiction Demand for fentanyl becomes inelastic following extended access to fentanyl vapor self-administration Effects of chronic fentanyl administration on behavioral characteristics of mice Divergent profiles of fentanyl withdrawal and associated pain in mice and rats Impact of morphine dependence and withdrawal on the reinforcing effectiveness of fentanyl, cocaine, and methamphetamine in rats Differences in antinociceptive signalling mechanisms following morphine and fentanyl microinjections into the rat periaqueductal gray Lack of antinociceptive cross-tolerance with co-administration of morphine and fentanyl into the periaqueductal gray of male Sprague-Dawley rats Effects of fentanyl on acute locomotor activity, behavioral sensitization, and contextual reward in female and male rats Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats Remifentanil self-administration in mice promotes sex-specific prefrontal cortex dysfunction underlying deficits in cognitive flexibility Sex-dependent effects of an Hnrnph1 mutation on fentanyl addiction-relevant behaviors but not antinociception in mice Structural assessment of agonist efficacy in the l-opioid receptor: morphine and fentanyl elicit different activation patterns Molecular dynamics of fentanyl bound to l-opioid receptor Fentanyl family at the mu-opioid receptor: uniform assessment of binding and computational analysis How l-opioid receptor recognizes fentanyl Molecular mechanisms of fentanyl mediated b-arrestin biased signaling Effect of fentanyl and its three novel analogues on biochemical, oxidative, histological, and neuroadaptive markers after sub-acute exposure in mice A high dose of fentanyl may accelerate the onset of acute postoperative pain Determination of fentanyl, alpha-methylfentanyl, beta-hydroxyfentanyl, and the metabolite norfentanyl in rat urine by LC-MS/ MS Affinity of fentanyl and its derivatives for the r 1 -receptor Fentanyl but not morphine interacts with nonopioid recombinant human neurotransmitter receptors and transporters Blockade of the human ether A-go-go-related gene (hERG) potassium channel by fentanyl Fentanyl-induced block of hERG channels is exacerbated by hypoxia, hypokalemia, alkalosis, and the presence of hERG1b Fentanyl inhibits lung cancer viability and invasion via upregulation of miR-331-3p and repression of HDAC5 Fentanyl inhibits acute myeloid leukemia differentiated cells and committed progenitors via opioid receptor-independent suppression of Ras and STAT5 pathways Fentanyl inhibits the progression of gastric cancer through the suppression of MMP-9 via the PI3K/Akt signaling pathway Fentanyl stimulates tumor angiogenesis via activating multiple proangiogenic signaling pathways Respiratory effects of low and high doses of fentanyl in control and b-arrestin 2-deficient mice Safety and efficacy of ketamine versus ketamine-fentanyl-dexmedetomidine combination for anesthesia and analgesia in rats Enduring consequences of perinatal fentanyl exposure in mice Perinatal fentanyl exposure leads to long-lasting impairments in somatosensory circuit function and behavior Fentanyl inhibits air puff-evoked sensory information processing in mouse cerebellar neurons recorded in vivo Morphine and fentanyl exposure during therapeutic hypothermia does not impair neurodevelopment Ventral tegmental area: Cellular heterogeneity, connectivity and behaviour The dopamine theory of addiction: 40 years of highs and lows Ghrelin receptor antagonism of fentanyl-induced conditioned place preference, intravenous selfadministration, and dopamine release in the nucleus accumbens in rats Opioid withdrawal produces sex-specific effects on fentanyl-vs.-food choice and mesolimbic transcription Orexin receptor antagonists as emerging treatments for psychiatric disorders Targeting the orexin system for prescription opioid use disorder Intermittent selfadministration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system The role of orexin-1 receptor signaling in demand for the opioid fentanyl Fentanyl and naloxone effects on glutamate and GABA release rates from anterior hypothalamus in freely moving rats Role of BNST CRFR1 receptors in incubation of fentanyl seeking The effect of fentanyl and morphine on neurons in the dorsal raphe nucleus in the rat: An in vitro study Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors Autoradiographic mapping of l-opioid receptors during opiate tolerance and supersensitivity in the rat central nervous system Effects of parecoxib and fentanyl on nociception-induced cortical activity Altered functional connectivity in an aged rat model of postoperative cognitive dysfunction: A study using resting-state functional MRI Role of projections between piriform cortex and orbitofrontal cortex in relapse to fentanyl seeking after palatable food choice-induced voluntary abstinence A piriform-orbitofrontal cortex pathway drives relapse to fentanyl-seeking after voluntary abstinence The effects of anaesthetics and sedatives on brain inflammation Self-administered fentanyl profoundly impacts rat brain innate immune targets Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats Increased hyperalgesia and proinflammatory cytokines in the spinal cord and dorsal root ganglion after surgery and/or fentanyl administration in rats Morphine and fentanyl repeated administration induces different levels of NLRP3-dependent pyroptosis in the dorsal raphe nucleus of male rats via cell-specific activation of TLR4 and opioid receptors Protective role of fentanyl in lipopolysaccharide-induced neuroinflammation in BV-2 cells The gut-brain interaction in opioid tolerance The role of the gut microbiome in opioid use Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model The gut microbiota mediates reward and sensory responses associated with regimen-selective morphine dependence SnapShot: The microbiota-gut-brain axis Neuroimmune mechanisms of psychostimulant and opioid use disorders Gut microbiota modulates the inflammatory response and cognitive impairment induced by sleep deprivation Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl Methocinnamox reverses and prevents fentanyl-induced ventilatory depression in rats Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys Effects of kappa opioid receptor agonists on fentanyl vs. food choice in male and female rats: Contingent vs. non-contingent administration Levo-tetrahydropalmatine attenuates the acquisition of fentanyl-induced conditioned place preference and the changes in ERK and CREB phosphorylation expression in mice Effects of 5-HT 2A receptor stimulation on economic demand for fentanyl after intermittent and continuous access self-administration in male rats A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats A novel approach to treating opioid use disorders: Dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y 2 receptors Effects of the glucocorticoid receptor antagonist PT150 on stress-induced fentanyl seeking in male and female rats Fentanyl overdose causing hippocampal ischaemia followed by delayed leukoencephalopathy The effects of morphine, methadone, and fentanyl on mitochondria: A live cell imaging study Fentanyl can be mitochondriontoxic depending on dosage and cell type Electrocortical changes associating sedation and respiratory depression by the opioid analgesic fentanyl Noradrenergic mechanisms in fentanyl-mediated rapid death explain failure of naloxone in the opioid crisis D-amphetamine accelerates recovery of consciousness and respiratory drive after high-dose fentanyl in rats Cannabinoid CB 2 receptor activation attenuates fentanylinduced respiratory depression Calabadion 1 selectively reverses respiratory and central nervous system effects of fentanyl in a rat model Activating a4b2 nicotinic acetylcholine receptors alleviates fentanyl-induced respiratory depression in rats Oxytocin receptor activation rescues opioid-induced respiratory depression by systemic fentanyl in the rat Systemic administration of tempol attenuates the cardiorespiratory depressant effects of fentanyl Vaccines to treat opioid use disorders and to reduce opioid overdoses Development of vaccines to treat opioid use disorders and reduce incidence of overdose Vaccines to combat the opioid crisis: Vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse Immunopharmacotherapies for treating opioid use disorder A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats Synthesis and biological evaluation of a lipopeptide-based methamphetamine vaccine Preclinical evaluation of vaccines to treat opioid use disorders: How close are we to a clinically viable therapeutic? A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats Combatting synthetic designer opioids: A conjugate vaccine ablates lethal doses of fentanyl class drugs Conjugate vaccine produces long-lasting attenuation of fentanyl vs. food choice and blocks expression of opioid withdrawal-induced increases in fentanyl choice in rats Utility of fentanyl vaccines: Unique challenges posed by preventing opioid overdose and treating opioid use disorder Discriminative stimulus effects of carfentanil in rats discriminating fentanyl: Differential antagonism by naltrexone A highly efficacious carfentanil vaccine that blunts opioidinduced antinociception and respiratory depression Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge Novel vaccine that blunts fentanyl effects and sequesters ultrapotent fentanyl analogues Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity A fentanyl vaccine constructed upon opsonizing antibodies specific for the Gala1-3Gal epitope A synthetic opioid vaccine attenuates fentanyl-vsfood choice in male and female rhesus monkeys Vaccine blunts fentanyl potency in male rhesus monkeys Monoclonal antibodies for combating synthetic opioid intoxication Monoclonal antibodies counteract opioidinduced behavioral and toxic effects in mice and rats Developing translational vaccines against heroin and fentanyl through investigation of adjuvants and stability Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin Evaluation of a dual fentanyl/heroin vaccine on the antinociceptive and reinforcing effects of a fentanyl/ heroin mixture in male and female rats Bivalent conjugate vaccine induces dual immunogenic response that attenuates heroin and fentanyl effects in mice A chemically contiguous hapten approach for a heroin-fentanyl vaccine Improved admixture vaccine of fentanyl and heroin hapten immunoconjugates: Antinociceptive evaluation of fentanyl-contaminated heroin Efficacious vaccine against heroin contaminated with fentanyl Evaluation of soluble fentanyl microneedles for locoregional anti-nociceptive activity A meta-analysis of acupuncture combined with opioid receptor agonists for treatment of opiate-withdrawal symptoms Traditional Chinese medicine in treatment of opiate addiction Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China The authors declare that they do not have any conflicts of interest.